Sandoz sued over sterile solution

Biopharmaceutical company Omeros has filed a complaint against Sandoz for allegedly infringing its patent covering Omidria (phenylephrine and ketorolac).

Omidria is a sterile solution concentrate.

The complaint was filed on Wednesday, June 21, at the US District Court for the District of New Jersey.

The case arose after Sandoz filed an Abbreviated New Drug Application with the Food and Drug Administration to market a generic version of the sterile solution.

Omidria is covered by four patents which are US numbers 8,586,633; 9,066,856; 9,399,040 and 9,486,406.

The company has asked the district court for an award of damages, as well as cost for bringing the case to court.

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.